Almost all patients who received an experimental pancreatic cancer vaccine developed an immune
Pancreatic Cancer Vaccine Triggers Immune Response in 98.9 Percent of Patients
Almost all patients who received an experimental pancreatic cancer vaccine developed an immune response against the KRAS gene, according to findings published in Nature Medicine. Despite the high rate of cellular immune activation, a Phase 2 clinical trial revealed no statistically significant difference in disease-free survival between the vaccinated cohort and the control group.
- An experimental pancreatic cancer vaccine called camupepimut produced increased T-cell responses against mutated KRAS genes in 98.9 percent of evaluable patients.
- A Phase 2 randomized study involving 144 surgical and chemotherapy patients found no statistically significant improvement in disease-free survival compared to the control group.
High Recurrence Rates Drive Experimental KRAS Vaccine Trials
Pancreatic cancer remains notoriously difficult to treat, with malignant tumors recurring in up to 80 percent of patients even after surgical intervention and chemotherapy. Patients carrying specific genetic alterations face an especially high risk of relapse. Mutations in the KRAS gene are identified in approximately 90 percent of pancreatic ductal adenocarcinomas, which represent the most common form of the disease.
The Phase 2 clinical trial evaluated 144 patients with KRAS mutations who had already undergone surgery and chemotherapy. At the baseline of the study, none of the participants displayed visible signs of cancer on imaging scans. Researchers randomized 96 patients to receive the experimental vaccine, while 48 individuals formed the control group, as detailed in reports from România Liberă.
Experimental Vaccine Trains Immune Cells to Attack KRAS Mutations
The experimental vaccine, designated camupepimut, is engineered to train immune cells to recognize and attack malignant cells expressing seven frequent mutations of the KRAS gene. These specific mutations assist pancreatic tumors in surviving and proliferating within the body. Out of the 96 patients assigned to the vaccine group, 90 were evaluable for immunological outcomes.
The data demonstrated that 98.9 percent of those evaluable patients developed heightened T-cell responses against mutated KRAS. In more than 80 percent of recipients, the T-cell response exceeded ninefold pre-vaccination levels. Ben George, lead author of the study from the Mayo Clinic, noted that pancreatic cancer has historically proven resistant to immunotherapy.
“Ceea ce este încurajator este că am reușit să generăm un răspuns imun puternic împotriva mutațiilor KRAS la aproape fiecare pacient pe care l-am evaluat. Într-o analiză exploratorie, pacienții cu răspunsuri imune mai mari la vaccin au părut protejați, cu timpi mai lungi de supraviețuire fără boală,” stated Ben George.
Expressed in English, Dr. George emphasized that generating a powerful immune response against KRAS mutations in nearly every evaluated patient represents an encouraging milestone, with exploratory analyses hinting at prolonged protection for those exhibiting the highest immune activation.
Although the trial successfully established biological proof-of-principle regarding immune system engagement, the absence of a statistically significant survival benefit leaves the clinical utility of camupepimut unproven at this stage. The therapy targets the lymph nodes and, to date, appears to reach these areas and successfully modify the immune response, but investigators emphasize that this immunological shift does not yet confirm the prevention of disease recurrence.
To address these open questions, researchers are designing a Phase 3 clinical trial that will incorporate additional booster doses of the vaccine.
Parallels are being drawn to messenger RNA cancer vaccines. In separate Phase 3 trials involving melanoma, a personalized mRNA vaccine combined with standard immunotherapy reduced the risk of recurrence or death by 42 percent compared to standard treatment alone. While the pancreatic vaccine did not match that clear clinical benefit in its latest iteration, researchers point to separate ongoing studies of personalized mRNA vaccines where a subset of pancreatic cancer patients with reactive immune systems remain healthy years after treatment.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.